Gamma Pharmaceuticals inks brokerage agreement with J&A Lazier Racing

NewsGuard 100/100 Score

Gamma Pharmaceuticals Inc. (the "Company") (PINKSHEETS: GMPM) announced it has signed a Product Brokerage Agreement with J&A Lazier Racing LLC of California. Mr. Lazier, an accomplished Indy Car Driver, will benefit from Gamma's Professional Grade vitamin supplements, nutritional and energy products to ensure peak athletic performance during the demanding Indy Car season. Gamma will make the products developed for the Indy Car race conditions available to consumers worldwide through Gamma's global distribution platform.

Peter Cunningham, Gamma's CEO, stated, "We are thrilled to be in business with such an elite global athlete and personality. Gamma will be Mr. Lazier's off-track pit crew. The objective is to keep Mr. Lazier in peak performance condition for the Indy Car season."

The Product Brokerage Agreement supports Gamma's entry into the world of Indy Car Racing. Indy Car Racing is the premier motor sport in the US with a substantial domestic and global following. The sport fits Gamma's global identity and up-market brand profile. The Indianapolis 500 is the largest single day sporting event in the world, attracting nearly 150 million television viewers and approximately 500,000 spectators. Gamma has built a full promotional and marketing program designed to attract motor sports fans to Gamma's branded products.

Source:

Gamma Pharmaceuticals Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Georgetown study raises concerns over aspirin's role in breast cancer treatment